Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Alkermes Initiates Two New Clinical Trials Of ALKS 33
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of two new clinical trials of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other nervous system disorders. Study ALK33-004 is a phase 1 clinical trial designed to examine the ability of ALKS 33 to block the effects of an opioid following a single oral dose of ALKS 33 in healthy, non-dependent, opioid-experienced subjects. Study ALK33-003 is a phase 1 clinical trial designed to evaluate the pharmacokinetics, safety and tolerability of multiple doses of ALKS 33 in healthy volunteers.
generic viagra online
British Climate Act 'Failed Before It Started'
The British Climate Act is flawed and comprised of unrealistic and unobtainable targets, writes US academic Roger A Pielke Jr, in a journal paper published on the 18th June, 2009, in IOP Publishing"s Environmental Research Letters.
News of the day
Surgical Mask And Respirator Use Should Be Encouraged During Swine Flu Outbreak
A new article in the journal Risk Analysis assessed various ways in which aerosol transmission of the flu, a central mode of diffusion which involves breathing droplets in the air, can be reduced. Results show that face protection is a key infection control measure for influenza and can thus affect how people should try to protect themselves from the swine flu.
Diagnostics

PhRMA's Tally: $40 Million To Lobby On Health Care

NPR reports on one of the most powerful players in health care: the Pharmaceutical Research and Manufacturers of America, or PhRMA. In addition to spending $40 million, PhRMA alone has 29 people lobbying for it and has "hired 45 different Washington, D.C., lobbying firms to represent it in those three months of the second quarter." NPR reports: "It represents just 32 brand-name drug companies, but it has so much influence that when Congress passes a bill, PhRMA almost always gets its way." "Any firm that spends significant money lobbying Congress has to file a quarterly report. Monday was the deadline for the second quarter, providing a chance to peer into three critical months in the health care debate: April, May and June. That"s when Congress really got down to business with health care. In those three months, PhRMA spent just over $6 million, which breaks down to about $2 million a month. But the reports filed by the companies that belong to PhRMA reveal that during this same period, all but a few of them were running their own lobby shops as well." PhRMA has been advertising and its CEO has been emphasizing the group"s support for reform. NPR notes that if you want to see how PhRMA is influencing the debate, look at what issues have been removed from the table, such as drug re-importation from Canada. "This is not to pass judgment on the merits of PhRMA"s arguments, but rather to show just how much money and lobbying it uses to back them up - and the winning streak in Congress that follows" (Seabrook and Overby, 7/23). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009